Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, May 22, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Anupam Rama Upgraded (ANAB) to Hold and Decreased Target to $30 on, May 22nd, 2023
Anupam Rama of JP Morgan, Upgraded "AnaptysBio, Inc." (ANAB) to Hold and Decreased Target from $31 to $30 on, May 22nd, 2023.
Anupam has made no other calls on ANAB in the last 4 months.
There are 2 other peers that have a rating on ANAB. Out of the 2 peers that are also analyzing ANAB, 1 agrees with Anupam's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- David Nierengarten of "Wedbush" Reiterated at Hold and Held Target at $29 on, Friday, May 12th, 2023
This is the rating of the analyst that currently disagrees with Anupam
- Yatin Suneja of "Guggenheim" Maintained at Strong Buy with Increased Target to $45 on, Friday, May 12th, 2023
